Molecular markers of early cervical neoplasia

Diagnostic Histopathology

Volumn 16, Issue 10, 2010, Pages 445-454

  Pinto, Alvaro P ^a   Crum, Christopher P ^a,b   Hirsch, Michelle S ^a,b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Biomarker; Cervical biopsy; Cervical intraepithelial neoplasia (CIN); Cervix neoplasia; HPV; Immunohistochemistry; Liquid based cytology; MIB 1; P16INK4A; ProEx C; Squamous intraepithelial lesion (SIL)

Indexed keywords

KI 67 ANTIGEN; MOLECULAR MARKER; PROTEIN P16;

ARTICLE; CANCER DIAGNOSIS; CYTOLOGY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

EID: 77956872226     PISSN: 17562317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mpdhp.2010.06.012     Document Type: Article

References (25)

1. Stoler M.H., Schiffman M., Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001, 285:1500-1505.
2. Nucci M.R., Crum C.P. Redefining early cervical neoplasia: recent progress. Adv Anat Pathol 2007, 14:1-10.
3. Syrjänen K.J. Immunohistochemistry in assessment of molecular pathogenesis of cervical carcinogenesis. Eur J Gynaecol Oncol 2005, 26:5-19.
4. Lorenzato M., Caudroy S., Bronner C., et al. Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions?. Hum Pathol 2005, 36:1101-1107.
5. Sahebali S., Depuydt C.E., Boulet G.A., et al. Immunocytochemistry in liquid-based cervical cytology: analysis of clinical use following a cross-sectional study. Int J Cancer 2006, 118:1254-1260.
6. Wentzensen N., Klug S.J. Early detection of cervical carcinomas: finding an overall approach. Dtsch Arztebl Int 2008, 105:617-622.
7. Pinto A.P., Schlecht N.F., Woo T.Y., Crum C.P., Cibas E.S. Biomarker (ProEx C, p16(INK4A), and MiB-1) distinction of high-grade squamous intraepithelial lesion from its mimics. Mod Pathol 2008, 21:1067-1074.
8. Conesa-Zamora P., Doménech-Peris A., Orantes-Casado F.J., et al. Effect of human papillomavirus on cell cycle-related proteins p16, Ki-67, Cyclin D1, p53, and ProEx C in precursor lesions of cervical carcinoma: a tissue microarray study. Am J Clin Pathol 2009, 132:378-390.
9. Keating J.T., Ince T., Crum C.P. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol 2001, 8:83-92.
10. Hariri J., Øster A. The negative predictive value of p16INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix. Int J Gynecol Pathol 2007, 26:223-228.
11. Negri G., Bellisano G., Zannoni G.F., et al. p16 ink4a and HPV L1 immunohistochemistry is helpful for estimating the behavior of low-grade dysplastic lesions of the cervix uteri. Am J Surg Pathol 2008, 32:1715-1720.
12. Iaconis L., Hyjek E., Ellenson L.H., Pirog E.C. p16 and Ki-67 immunostaining in atypical immature squamous metaplasia of the uterine cervix: correlation with human papillomavirus detection. Arch Pathol Lab Med 2007, 131:1343-1349.
13. Wang S.S., Trunk M., Schiffman M., et al. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004, 13:1355-1360.
14. Tsoumpou I., Arbyn M., Kyrgiou M., et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009, 35:210-220.
15. Park J.J., Sun D., Quade B.J., et al. Stratified mucin-producing intraepithelial lesions of the cervix: adenosquamous or columnar cell neoplasia?. Am J Surg Pathol 2000, 24:1414-1419.
16. van Hamont D., Bulten J., Shirango H., Melchers W.J., Massuger L.F., de Wilde P.C. Biological behavior of CIN lesions is predictable by multiple parameter logistic regression models. Carcinogenesis 2008, 29:840-845.
17. Walts A.E., Bose S. Is the expression pattern of BD ProExC the same as Ki-67? A comparative analysis in cervical biopsies. Appl Immunohistochem Mol Morphol 2010, 18:262-267.
18. Shi J., Liu H., Wilkerson M., et al. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions. Hum Pathol 2007, 38:1335-1344.
19. Badr R.E., Walts A.E., Chung F., Bose S. BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol 2008, 32:899-906.
20. Siddiqui M.T., Cohen C., Nassar A. Detecting high-grade cervical disease on ASC-H cytology: role of BD ProEx C and Digene Hybrid Capture II HPV DNA testing. Am J Clin Pathol 2008, 130:765-770.
21. Beccati M.D., Buriani C., Pedriali M., Rossi S., Nenci I. Quantitative detection of molecular markers ProEx C (minichromosome maintenance protein 2 and topoisomerase IIa) and MIB-1 in liquid-based cervical squamous cell cytology. Cancer 2008, 114:196-203.
22. Kelly D., Kincaid E., Fansler Z., Rosenthal D.L., Clark D.P. Detection of cervical high-grade squamous intraepithelial lesions from cytologic samples using a novel immunocytochemical assay (ProEx C). Cancer 2006, 108:494-500.
23. Walts A.E., Bose S. p16, Ki-67, and BD ProExC immunostaining: a practical approach for diagnosis of cervical intraepithelial neoplasia. Hum Pathol 2009, 40:957-964.
24. Banet N, Livasy C. Evaluation of the combined utility of p16 and ProEx C immunohistochemistry in distinguishing endocervical glandular neoplasia from its benign glandular mimics. Abstract, USCAP meeting, 2010.
25. Carozzi F., Confortini M., New Technologies for Cervival Cancer Screening (NTCC) Working Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008, 9:937-945.